Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
blinatumomab expanded t-cells
- Development stage
- Unknown
- Lead developer
- Papa Giovanni XXIII Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Blinatumomab Expanded T-cells (BET) is an autologous cell therapy product developed by the Papa Giovanni XXIII Hospital for the treatment of CD20+ indolent non-Hodgkin lymphomas (iNHL) and chronic lymphocytic leukemia (CLL). The therapy involves the ex vivo expansion of a patient's own T cells (polyclonal CD4+ and CD8+ cells) using the bispecific T-cell engager (BiTE) blinatumomab and recombinant human interleukin-2 (rhIL-2). During the expansion process, blinatumomab cross-links CD3 on T cells with CD19 on contaminating neoplastic B cells, leading to the activation of T cells and the simultaneous elimination of tumor cells. The resulting Advanced Therapeutic Medicinal Product (ATMP) is infused back into the patient to facilitate immune reconstitution and potentially provide anti-tumor activity following immunosuppressive chemotherapy regimens like FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab).
- Other names
- Blinatumomab-expanded T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on blinatumomab expanded t-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on blinatumomab expanded t-cells.